Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Are The Growth Projections For The Radiopharmaceutical Theranostics Market Size During 2025–2029?
The radiopharmaceutical theranostics market has observed significant growth recently. Its size is expected to increase from $2.88 billion in 2024 to $3.27 billion in 2025, at a compound annual growth rate (CAGR) of 13.5%. Historically, this expansion has been driven by radiopharmaceutical development, progress in clinical research, investments in research, regulatory approvals, and advancements in nuclear medicine.
The radiopharmaceutical theranostics market size is expected to experience significant expansion in the coming years. This market is projected to reach $5.74 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 15.1%. Factors contributing to this growth during the forecast period encompass biomarker discovery and validation, genomic and proteomic technologies, advancements in precision radiotherapy, increased interdisciplinary collaborations, and enhanced patient advocacy and support. Key developments anticipated within the forecast period include ethical and legal considerations, the integration of telemedicine in theranostics, a focus on patient-centric care, tailored radiopharmaceutical customization, and the evolution of nano-theranostics.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=11951&type=smp
Which Factors And Drivers Are Influencing The Radiopharmaceutical Theranostics Market In 2025?
The increasing incidence of cancer is anticipated to propel the growth of the radiopharmaceutical theranostics market going forward. Cancer is defined as a disease or condition marked by the complex and abnormal proliferation of cells that can infiltrate and disseminate to other parts of the body. Radiopharmaceutical theranostics assists in cancer treatment through targeted and personalized approaches. For instance, in 2023, according to the American Cancer Society, a US-based voluntary cancer health organization, it was estimated that 1.9 million new cancer cases would be diagnosed in the US, and about 609,820 deaths might occur due to cancer. Additionally, 88% of those diagnosed are expected to belong to the 50 years or above age group. Therefore, the rising incidence of cancer is a key driver for the growth of the radiopharmaceutical theranostics market.
What Are The Emerging Segments Gaining Attention In The Radiopharmaceutical Theranostics Market?
The radiopharmaceutical theranosticsmarket covered in this report is segmented –
1) By Product Type: Alpha Emitters; Beta Emitters; Positron Emission Tomography (PET) Tracers
2) By Source: Nuclear Reactors; Cyclotrons
3) By Radioisotope: Technetium-99; Gallium-68; Iodine-131; Iodine-123; 18F; Y-90; Lutetium (Lu) 177; Copper (Cu) 67; Copper (Cu) 64; Other Radioscopes
4) By Indication: Oncology; Cardiology; Neurology; Other Indications
5) By End User: Hospitals; Diagnostic Imaging Centers; Academic And Research Institutes; Other End Users
Subsegments:
1) By Alpha Emitters: Actinium-225; Radium-223; Bismuth-213; Other Alpha-Emitting Radiopharmaceuticals
2) By Beta Emitters: Iodine-131; Lutetium-177; Yttrium-90; Other Beta-Emitting Radiopharmaceuticals
3) By Positron Emission Tomography (PET) Tracers: Fluorodeoxyglucose (FDG); Gallium-68; Carbon-11; Other PET Tracers
What Are The Major Trends Driving The Growth Of The Radiopharmaceutical Theranostics Market?
Leading firms within the radiopharmaceutical theranostics sector are embracing strategic collaborations to create novel treatments. These alliances benefit radiopharmaceutical theranostics enterprises by pooling resources and specialized knowledge, improving their research and development strengths, broadening their market presence, and hastening product commercialization, thereby stimulating progress and expansion across the radiopharmaceutical theranostics industry. An illustrative example is from March 2023, when Radiopharm Theranostics, an Australian biotechnology firm, formed a collaboration with Pharma15 Corporation, a US-based company, to produce advanced therapeutic radiopharmaceuticals intended for prostate cancer. This specific initiative concentrates on overcoming the resistance encountered with current PSMA-targeted treatments and improving selectivity to lessen harm to healthy tissues.
Who Are The Major Companies Operating In The Radiopharmaceutical Theranostics Market?
Major companies operating in the radiopharmaceutical theranostics market include Cardinal Health Inc., GE HealthCare Technologies Inc., Bayer AG, China Grand Pharmaceutical & Healthcare., Lantheus Medical Imaging Inc., Curium Pharma, Advanced Accelerator Applications, Telix Pharmaceuticals Ltd., Bracco Imaging S.p.A, NTP Radioisotopes SOC Ltd., Navidea Biopharmaceuticals Inc., Jubilant DraxImage Inc., NorthStar Medical Radioisotopes LLC, Blue Earth Diagnostics Ltd., Precirix NV, SpectronRx, Viewpoint Molecular Targeting Inc., NuView Life Sciences, Alpha-9 Theranostics Inc., RadioMedix Inc, RayzeBio Inc, Fusion Pharmaceuticals Inc, Actinium Pharmaceuticals Inc., Eckert & Ziegler Strahlen- und Medizintechnik AG, Ariceum Therapeutics GmbH, Radiopharm Theranostics Ltd, Ratio Therapeutics Inc, Primo Biotechnology, Bivision Biomedical Technology (Nanjing) Co. Ltd.
Download The Full Report For Exclusive Market Findings:
Which Region Is Expected To Witness The Fastest Growth In The Radiopharmaceutical Theranostics Market?
North America was the largest region in the radiopharmaceutical theranostics market in 2024. The regions covered in the radiopharmaceutical theranostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Radiopharmaceutical Theranostics Market Report:
https://www.thebusinessresearchcompany.com/customise?id=11951&type=smp
Browse Through More Reports Similar to the Global Radiopharmaceutical Theranostics Market 2025, By The Business Research Company
Software Products Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/software-products-global-market-report
Healthcare Cloud Computing Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/healthcare-cloud-computing-global-market-report
Software As A Service Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/software-as-a-service-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model